Context Therapeutics (CNTX) Stock: Buy, Sell, or Hold?
CNTX - Context Therapeutics Inc. Common Stock
$0.24
0.00 (-1.72%)
▼
5d:
-21.38%
30d:
-34.85%
90d:
-61.94%
WAIT
LOW Confidence
Analysis Updated: Oct 16, 2026 12:00 AM ET
Earnings: Nov 04, 2026
15d
Get Alerted When CNTX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: CNTX is down 21.4% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: CNTX is down 21.4% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: CNTX is currently trading at $0.24, which is considered oversold relative to its 30-day fair value range of $0.28 to $0.37.
Technical Outlook: Technically, CNTX is in a downtrend. Immediate support is located at $0.22, while resistance sits at $0.36.
Market Sentiment: CNTX scores 35/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $4.03 (+1552.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CNTX is in a downtrend. Immediate support is located at $0.22, while resistance sits at $0.36.
Market Sentiment: CNTX scores 35/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $4.03 (+1552.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$0.28 -
$0.37
Company Quality Score
42/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.9%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (35/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 1552.7% below Wall St target ($4.03)
- WARNING: Composite score 42/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$0.28 -
$0.37
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.22
Resistance Level
$0.36
Current Trend
Downtrend
Technical data as of
Oct 19, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.56
Wall Street Target
$4.03
(+1552.7%)
Share & Embed Analysis
Last updated: October 19, 2026 3:03 PM ET
Data refreshes hourly during market hours. Next update: 4:03 PM
Data refreshes hourly during market hours. Next update: 4:03 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CNTX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
22 analysts |
$295 | 52 HOLD |
|
REGN
Regeneron Pharmaceutical… |
BUY
28 analysts |
$864 | 41 HOLD |
|
PRAX
Praxis Precision Medicin… |
STRONG BUY
20 analysts |
$650 | 57 HOLD |
|
DYN
Dyne Therapeutics Inc |
STRONG BUY
17 analysts |
$36 | 61 BUY |
|
ACAD
ACADIA Pharmaceuticals I… |
STRONG BUY
20 analysts |
$31 | 60 BUY |
